PureCycle Technologies, Inc. (PCT) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2024. PureCycle Technologies, Inc. is a Florida-based corporation commercializing patented purification recycling technology to convert waste polypropylene into ultra-pure recycled (UPR) resin. The company operates its first commercial-scale facility in Ironton, Ohio, and is developing a multi-line facility in Augusta, Georgia. As of June 30, 2024, the company had approximately 164.96 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenue | Immaterial (Not explicitly quantified) | Immaterial |
| Net Loss | $(133.8) million | $(81.2) million |
| Loss Per Share (Diluted) | $(0.81) | $(0.50) |
| Operating Costs & Expenses | $78.9 million | $48.4 million |
| Interest Expense | $27.1 million | $4.7 million |
| Cash and Cash Equivalents | $10.9 million | $28.9 million (as of June 30, 2023) |
| Restricted Cash | $12.6 million | $187.4 million (as of June 30, 2023) |
| Total Debt (Gross) | $370.3 million | $564.2 million |
| Working Capital | $(15.7) million | $107.0 million (Dec 31, 2023) |
Material Changes vs. Prior Period
- Liquidity Shift: Total cash and restricted cash decreased significantly from $302.5 million at December 31, 2023, to $23.5 million at June 30, 2024. This was primarily due to the purchase of 99% of outstanding Revenue Bonds in March 2024, which utilized $253.2 million in cash (including restricted funds).
- Debt Restructuring: The company extinguished a significant portion of its Revenue Bonds and issued new Related Party Revenue Bonds ($94.3 million par) to Pure Plastic LLC. This resulted in a $21.2 million loss on debt extinguishment recorded in Q1 2024.
- Operating Expenses: Operating costs increased by 129% year-over-year for the six-month period, driven by higher depreciation ($12.3 million increase) and operational site costs ($11.6 million increase) at the Ironton Facility.
- Warrant Liability: The change in fair value of warrants resulted in a benefit of $9.6 million for the six months ended June 30, 2024, compared to an expense of $31.1 million in the prior year period.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management disclosed conditions that raise substantial doubt about the company's ability to continue as a going concern for one year from the filing date. However, management believes this doubt is alleviated by plans to re-market purchased bonds and achieve operational progress. Unrestricted liquidity is currently insufficient to fund operations and commitments without additional financing.
- Operational Challenges: The Ironton Facility has not reached meaningful production volumes. The company faces intermittent mechanical challenges, specifically regarding the removal of polyethylene and other solids ("Co-product 2" or CP2), which impacts production rates and product consistency.
- Capital Requirements: The company anticipates needing an additional $5.0 to $8.0 million for the Ironton Facility and has approximately $46.5 million in other capital commitments for the Augusta Facility and Feed PreP facilities. Future financing (debt or equity) is required.
- Legal Proceedings:
- Securities Litigation: A tentative settlement of $12 million was reached for the Consolidated Theodore Lawsuit, subject to court approval.
- Derivative Litigation: A proposed settlement of $3 million (plus corporate therapeutics) was reached for consolidated derivative lawsuits (Ayers, Brunson), subject to court approval.
- Arbitration: An ongoing arbitration with Denham-Blythe Company, Inc. seeks approximately $17.0 million; the company intends to vigorously defend and counterclaim.
- Regulatory Milestone: On June 11, 2024, the FDA granted an expanded Letter of No Objection (LNO) allowing PCT's UPR resin to be used in contact with all food types under Conditions of Use A through H.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and certainty of re-marketing the purchased Revenue Bonds to generate unrestricted cash, as this is critical to the "going concern" assessment.
- Production Ramp-up: Monitor the resolution of the "Co-product 2" (CP2) mechanical issues at the Ironton Facility and the timeline for achieving consistent, on-spec production volumes.
- Legal Settlements: Confirm court approval and final funding of the $12 million securities settlement and the $3 million derivative settlement.
- Augusta Facility Financing: Assess the status of project financing for the Augusta Facility, given the company's statement that market conditions have created uncertainty regarding the timing of success.
- Debt Covenants: Review the amended indentures and credit agreements to understand the remaining covenants and the impact of the recent debt restructuring on future borrowing capacity.